AstraZeneca has amended two deals this week as the company determines its R&D investment priorities. Firstly, it added Japanese rights to its dapagliflozin collaboration for type 2 diabetes with Bristol-Myers Squibb (BMS) and secondly, AstraZeneca terminated the heat shock protein 90 (Hsp90) deal with Infinity Pharmaceuticals, which it inherited from MedImmune.